Study guide
2.4 Systemic Healing Factors and Medications
WOCNCB Certified Wound Care Nurse CWCN
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current CWCN Exam Facts 1.2 Eligibility: Traditional, Experiential, and WTA-C Credit 1.3 Fees, Retakes, Recertification, and Test Strategy
2 Skin Biology, History & Systemic Factors
2.1 Integumentary Anatomy and Skin Barrier 2.2 Healing Phases, Healing vs Non-Healing, and Biofilm 2.3 History, Psychosocial Factors, Nutrition, and Pain 2.4 Systemic Healing Factors and Medications
3 Diagnostics and the Focused Wound Exam
3.1 Vascular, Laboratory, Imaging, and Perfusion Studies 3.2 Wound Measurement, Periwound Signs, and Dermatologic Differentials 3.3 When and How to Culture a Wound
4 Pressure Injury Pathophysiology and Staging
4.1 Pressure Injury Pathophysiology and Risk Tools 4.2 NPIAP Stages 1 through 4 4.3 Unstageable, DTPI, MDRPI, and Mucosal Injuries
5 Lower-Extremity and Special Etiologies
5.1 Venous / LEVD Ulcer Assessment 5.2 Arterial / LEAD Ulcer Assessment and PAD Testing 5.3 Neuropathic Foot Ulcers, Charcot, and Wagner Grading 5.4 Mixed Disease, Atypical, Surgical, Traumatic, and Burn Wounds
6 Prevention and Support Surfaces
6.1 Risk-Based Prevention: Moisture, Nutrition, Mobility, Cognition 6.2 Repositioning, Shear Reduction, and Seating 6.3 Support Surface Types and Selection
7 Offloading, Moisture, and Skin Products
7.1 Offloading and Protective Footwear 7.2 MASD/IAD, MARSI Prevention, and Skin Care Products 7.3 Friction, Heel Protection, and Preventing Treatment Complications
8 Wound-Care Principles, Pain, and Studies
8.1 Moisture Balance, Dead Space, and Periwound Protection 8.2 Recommending Pain Management Modalities 8.3 Obtaining Cultures and Recommending Studies
9 Cleansing and Wound Bed Preparation
9.1 Wound Cleansing Regimens 9.2 TIME: Infection, Moisture, and Edge Optimization 9.3 Chemical Cauterization Indications
10 Debridement Modalities
10.1 Debridement Types, Indications, and Contraindications 10.2 Conservative Sharp vs Surgical/Excisional Debridement 10.3 Autolytic, Enzymatic, Biological, and Mechanical Debridement
11 Topical Therapies
11.1 Hydrating Dressings: Hydrogels, Films, Hydrocolloids 11.2 Absorbent Dressings: Foams, Alginates, Hydrofibers 11.3 Antimicrobials, Odor Control, and Periwound Integrity
12 Compression Therapy
12.1 Compression Types, Indications, and Contraindications 12.2 Static vs Dynamic Compression Application 12.3 Mixed Arterial-Venous Disease and Compression Safety
13 Advanced and Adjunctive Therapies
13.1 Negative Pressure Wound Therapy 13.2 HBOT, Bioengineered Tissue, and Leech Therapy 13.3 Hydrotherapy, Pulsed Lavage, Mist, Maggot Therapy, and Total Contact Casting
14 Patient-Centered Goals
14.1 Patient-Centered Care, Access, and Cultural Beliefs 14.2 Preventive, Palliative, Maintenance, and Curative Goals 14.3 Writing Patient-Focused Skin and Wound Goals
15 Evaluation, Modification, and Documentation
15.1 Evaluating Treatment Effectiveness 15.2 Interpreting Response and Modifying the Plan 15.3 Documentation, CMS Quality Context, and Surveillance
16 Patient and Caregiver Education
16.1 Health Literacy, Goals, and Teach-Back 16.2 Educating on Procedures, Skin Care, and Diagnostic Results 16.3 Modifiable Risk Factors and Resource Access
17 Educating Other Clinicians
17.1 Teaching Skin and Wound Principles, Procedures, and Goals 17.2 Infection Control, Repositioning, Moisture, Nutrition, and Trauma Avoidance for Teams 17.3 Recommending Non-Invasive and Invasive Next Steps
18 Collaboration, Referral, and Handoff
18.1 Support, Supply Access, Post-Acute Care, and Service Referrals 18.2 Referring for Studies and Specialty Consults 18.3 Handoff Communication Across Settings
2.4 Systemic Healing Factors and Medications
Key Takeaways Explain This Topic AI
Hyperglycemia, PAD, venous edema, heart failure, COPD hypoxia, CKD, anemia, autoimmune disease, cancer, and immunosuppression all change whether a wound can heal.
Systemic corticosteroids, many chemotherapeutics, and antiangiogenic drugs impair repair; anticoagulants mainly increase bleeding with debridement.
Nicotine vasoconstricts and reduces tissue oxygen; smoking cessation is a wound intervention.
Glycemic control is a wound-care intervention, not a separate medical afterthought.
A wound is not-healable until critical perfusion, nutrition, or immunosuppression problems are addressed; the honest goal then is maintenance, palliation, or ischemia protection.
Last updated: September 2026
2.4 Systemic Healing Factors and Medications
Quick Answer: Dressings cannot outrun ischemia, uncontrolled glucose, nicotine, high-dose steroids, or starvation. Name the systemic factor, treat it as part of wound care, and if it cannot be reversed, call the wound not-healable and protect rather than promise closure.
010102 (factors affecting wound healing) and 010309 (medications) are the host chapter of the focused exam. A perfect topical plan on a foot with an ankle-brachial index of 0.4 is a delay to vascular referral.
Comorbidities that change healability
Diabetes and hyperglycemia. High glucose impairs neutrophil chemotaxis and phagocytosis, stiffens vessels via glycation, and travels with neuropathy and PAD. An A1C of 11% is not background color on the problem list; it is a wound-bed toxin. Glycemic control is a wound intervention —as much as offloading a plantar ulcer. You still individualize targets in frail elders, but you do not ignore random glucoses of 300 mg/dL because a silver dressing was applied.
Peripheral artery disease (PAD / LEAD). Macrovascular inflow failure produces punched-out, poorly granulating ulcers, claudication or rest pain, and a wound that will not fill. Local angiogenesis cannot compensate for an occluded tibial artery. Revascularization, when possible, is the healing plan; topical therapy is protection until then.
Venous disease. Chronic venous hypertension produces edema that widens capillary gaps, deposits fibrin, and starves skin of oxygen despite palpable pulses. Compression (when arterial inflow allows) is systemic-factor treatment delivered at the limb.
Heart failure. Biventricular failure drives dependent edema, poor forward flow, and sometimes cachexia. Aggressive compression without a heart-failure plan can dump fluid centrally. The stalled leg ulcer may be a cardiac problem wearing a dressing.
COPD and tissue oxygenation. Hypoxemia, steroid courses, and smoking cluster here. Fibroblasts and neutrophils are oxygen-hungry. A sat of 86% on room air is a healing factor, not only a pulmonary one. Tissue oxygenation also falls with anemia, edema, and vasoconstriction.
CKD. Uremia, anemia of chronic disease, calcium-phosphate disorders, and protein-intake limits collide with wound protein needs. You coordinate with nephrology rather than blindly ordering 1.5 g/kg protein in a dialysis patient without a plan. Calciphylaxis, when present, is an atypical systemic wound, not a missed Stage 2.
Anemia. Low oxygen-carrying capacity slows every aerobic repair step. Iron deficiency from chronic drainage is common in large ulcers; transfusion thresholds remain a medical decision, but the CWCN flags the hemoglobin as relevant.
Autoimmune disease. Vasculitis, rheumatoid disease, and scleroderma produce atypical ulcers and are treated with immunosuppression that then impairs repair. Pyoderma gangrenosum is a pathergy problem: aggressive wide debridement can enlarge it. Systemic diagnosis first.
Cancer and immunosuppression. Tumor burden, malnutrition, chemotherapy, radiation-damaged microvasculature, and drugs such as transplant immunosuppressants all blunt proliferation. Neutropenia changes infection risk and culture urgency.
Age, mobility, smoking, oxygen
Age slows inflammation and thins dermis (section 2.1); it is a factor, not a reason to withhold indicated care. Mobility and activity determine pressure, shear, and calf-muscle-pump function. A patient who will not or cannot leave the chair is a venous and pressure problem at once. Smoking and nicotine (cigarettes, some vaping, nicotine replacement still delivers nicotine) cause cutaneous vasoconstriction, increase carbon monoxide, impair fibroblast function, and raise platelet stickiness. Nicotine cessation is wound therapy. Tissue oxygen is the common pathway: if the host cannot deliver O₂, granulation will not appear no matter which foam you chose.
Medications that impair healing or change procedures
Medication or exposure Dominant wound effect CWCN action
Systemic corticosteroids Blunt inflammation, impair collagen and epithelialization, raise infection and skin-tear risk Ask dose and duration; do not expect textbook granulation on 20 mg prednisone daily
Many chemotherapeutics Hit dividing keratinocytes and fibroblasts; mucositis and cytopenias Time elective debridement with oncology; watch for neutropenia
Antiangiogenic agents (for example bevacizumab) Block new vessel growth needed for granulation Treat as a reason a surgical or traumatic wound may stall; communicate with oncology
Anticoagulants and antiplatelets Not primarily anti-healing; increase bleeding with conservative sharp or excisional debridement Check the agent, INR/PTT when relevant, and modify setting or technique
NSAIDs Nuance: may theoretically dampen early inflammatory signaling; still widely used for pain Do not treat them as steroid-equivalents; do weigh bleeding and renal effects
Vasoconstrictors (vasopressors, some migraine ergot or triptan patterns, nicotine) Reduce cutaneous flow Weigh limb perfusion; on pressors, heel and sacral ischemia risk soars
Topical steroids on intact periwound skin for dermatitis are not the same as pharmacologic systemic steroids, but chronic potent topical steroids still thin local dermis.
Not-healable until the host is addressed
Wound-care programs often sort wounds as healable , maintenance , or non-healable (sometimes called palliative or non-healable ischemic). A CWCN should be able to say: this ulcer will not close until inflow is restored, glucose is treated, calories are available, or the antiangiogenic agent and high-dose steroid are modified—if they even can be. Until then, goals are odor and exudate control, pain, infection surveillance, pressure relief, and avoiding harmful debridement of ischemic eschar that is a biologic dressing.
Calling a wound not-healable is not nihilism. It stops the cycle of weekly sharp debridement into dry gangrene and the family promise that the new collagen dressing will grow a pulse.
Scenario. Ms. Chen, 68, has an ischemic heel ulcer, ABI 0.45, A1C 11.2%, continues to smoke, takes prednisone 20 mg daily for COPD flares, and recently started bevacizumab. The bed is pale with adherent eschar and no granulation after three weeks of moist dressings. You do not escalate to daily enzymatic debridement as if this were a healable Stage 3. You treat glycemic control, smoking, and vascular referral as first-line wound interventions, flag steroids and antiangiogenic therapy as repair blockers, keep the heel offloaded and dry-stable if that is the ischemic plan, and document a not-healable wound until perfusion and host factors change . Anticoagulation, if she is on it, would further limit how aggressively you debride, but it is not the reason the bed cannot granulate—the PAD and oxygen story is.